





like us on Facebook.com/SandostatinLARDepot

This recipe was created by our RealSupport™ nutritionist especially for our members. Remember, please talk to your health care provider to determine if this recipe or any other food is appropriate for you.

# SAVORY QUINOA BREAKFAST PORRIDGE

Prep time: 5 minutes



Cook time: 20 minutes



Ready in: 25 minutes

## Ingredients

- 1 tablespoon canola oil
- 1 cup uncooked tricolor quinoa, rinsed
- 2 cups low-fat milk
- 1/4 teaspoon salt
- 4 eggs
- 1 cup baby arugula
- ¼ cup pine nuts, toasted
- 1 tablespoon chives, finely chopped
- Black pepper, for serving

## **Steps**

- 1. Heat oil in medium saucepan over medium heat. Add quinoa and cook for 2 minutes, stirring frequently, until quinoa is toasted. Add low-fat milk and salt and increase heat to medium-high. Bring to boil, stirring occasionally, then reduce heat to medium-low. Cover and simmer until quinoa is tender and milk has been absorbed, about 20 minutes. Add more low-fat milk to soften texture as needed. Remove from heat and let cool slightly.
- 2. While porridge cooks, bring a large pot of water to a boil over mediumhigh heat. Add eggs and boil for 6 minutes. Remove eggs from water with slotted spoon and immediately rinse under cold water. Carefully peel eggs and slice in half.
- 3. To serve, spoon warm porridge into bowls. Top with arugula, soft-boiled egg, pine nuts, chives and black pepper.

Please note that Novartis Pharmaceuticals Corporation does not endorse the use of any foods highlighted in this article; all information is provided for educational purposes only. Use of any food in this recipe is not intended to treat or cure carcinoid syndrome. You are advised to speak to your health care provider before introducing new foods into your diet.

Please see Indications and Important Safety Information on page 2.

Please click here for full Prescribing Information.

<sup>\*</sup>Includes Sandostatin® (octreotide acetate) Immediate-Release Injection and Sandostatin® LAR Depot (octreotide acetate) for injectable suspension for all approved indications.

Brought to you by RealSupport<sup>™</sup>, a patient information and support program for those with the severe diarrhea and flushing of carcinoid syndrome. RealSupport<sup>™</sup> is provided by Novartis Pharmaceuticals Corporation, the maker of Sandostatin<sup>®</sup> LAR Depot (octreotide acetate) for injectable suspension. For more information about RealSupport<sup>™</sup> program offerings, please follow us on www.facebook.com/SandostatinLARDepot.

### INDICATIONS AND USAGE

Sandostatin® LAR Depot (octreotide acetate) for injectable suspension is indicated for patients in whom initial treatment with immediate-release Sandostatin® (octreotide acetate) Injection has been shown to be effective and tolerated for

- Long-term treatment of the severe diarrhea and flushing episodes associated with metastatic carcinoid tumors
- Long-term treatment of the profuse watery diarrhea associated with VIP-secreting tumors

In patients with carcinoid syndrome and VIPomas, the effect of Sandostatin Injection and Sandostatin LAR Depot on tumor size, rate of growth, and development of metastases has not been determined.

#### **IMPORTANT SAFETY INFORMATION**

**Warnings and Precautions:** Treatment with Sandostatin LAR Depot may affect gallbladder function, with postmarketing reports of gallstones resulting in complications (inflammation of the gallbladder, bile duct, and pancreas, and requiring surgical removal of the gallbladder); sugar metabolism; thyroid and heart function; and nutritional absorption, which may require monitoring by your doctor. Call your doctor if you experience signs or symptoms of gallstones or any of their complications.

**Before Taking Sandostatin LAR Depot:** Tell your doctor if you have a history of heart disease or are taking other medications, including cyclosporine, insulin, oral hypoglycemic agents, beta-blockers, and bromocriptine.

**Common Side Effects:** Most patients experience side effects at some time. Some common side effects you may experience include back pain, fatigue, headache, abdominal pain, nausea, and dizziness.

**Other Information:** Patients with carcinoid tumors and VIPomas should adhere closely to their scheduled return visits for reinjection in order to minimize exacerbation of symptoms.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.

Please click here for full Prescribing Information.

To learn more, call 1-888-NOW-NOVA (1-888-669-6682) or visit <u>us.sandostatin.com</u>



